Tyrosine kinase inhibitors (TKI) treatment of non-small cell lung cancer (NSCLC) patients (p) based on EGFR mutations (m) status in serum only.

被引：0
|
作者：
Capdevila, Laia
Carcereny, Enric
de Aguirre, Itziar
Cros, Sara
Queralt, Cristina
Moran, Teresa
Buges, Cristina
Mijangos, Erika
Pardo, Nuria
Rosell, Rafael
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[2] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain
[3] Hosp Gen Granollers, Granollers, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19088
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tyrosine kinase inhibitors (TKI) treatment of non-small cell lung cancer (NSCLC) patients (p) based on EGFR mutations (m) status in serum only
    Vila, L.
    Pardo, N.
    Cuadra, J. L.
    Capdevila, L.
    Moran, T.
    Carcereny, E.
    Queralt, C.
    De Aguirre, I.
    Taron, M.
    Rosell, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S822 - S822
  • [2] Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
    Raez, L. E.
    Baca, Y.
    Nagasaka, M.
    Nieva, J.
    Mandani, H.
    Wanderwalde, A.
    Borghaei, H.
    Naban, C.
    Langer, C.
    Socinsky, M. A.
    Lopes, G.
    Khan, H.
    Wozniak, A.
    Carracedo, C.
    Liu, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S597 - S597
  • [3] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors
    Benesova, Lucie
    Minarik, Marek
    Jancarikova, Dana
    Belsanova, Barbora
    Pesek, Milos
    [J]. ANTICANCER RESEARCH, 2010, 30 (05) : 1667 - 1671
  • [4] Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer
    Hunter, S.
    Nickless, G.
    Ghosh, S.
    Lal, R.
    Merrick, S. A.
    Montes, A.
    Smith, D.
    Spicer, J.
    Karapanagiotou, E.
    [J]. LUNG CANCER, 2017, 103 : S34 - S35
  • [5] Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI)
    Schmid, Sabine
    Gautschi, Oliver
    Rothschild, Sacha
    Mauti, Laetitia
    Mark, Michael
    Froesch, Patrizia
    Fruh, Martin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1505 - S1505
  • [6] EGFR MUTATION (M) STATUS IN SERUM ONLY TO TREAT NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS (P)
    Carcereny, Enric
    Moran, Teresa
    Capdevila, Laia
    Estival, Anna
    Fernandez, Olga
    Queralt, Crsitina
    Indacochea, Alberto
    De Aguirre, Itziar
    Buges, Crisitina
    Vila, Laia
    Taron, Miquel
    Rosell, Rafael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S876 - S876
  • [7] EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data
    Dulloo, Sean
    Almusarhed, Manar
    Chen, Ryan
    Akala, Oyeyemi
    Varadhan, Balaji
    Chauhan, Meera
    Ahmed, Samreen
    [J]. LUNG CANCER, 2021, 156 : S40 - S40
  • [8] RICTOR signaling modulates the activity of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutated non-small cell lung cancer (NSCLC)
    Fan, Ni
    Zou, Yiyu
    Halmos, Balazs
    Perez-Soler, Roman
    Cheng, Haiying
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [9] Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI)
    Raez, Luis E.
    Baca, Yasmine
    Carracedo, Carlos
    Vanderwalde, Ari
    Nabhan, Chadi
    Nagasaka, Misako
    Nieva, Jorge
    Mandani, Hirva
    Borghaei, Hossein
    Socinski, Mark
    Khan, Hina
    Wozniak, Antoinette
    Lopes, Gilberto
    Liu, Stephen
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : S3 - S3
  • [10] EGFR tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer
    Kowalski, D. M.
    Krzakowski, M.
    Jaskiewicz, P.
    Janowicz-Zebrowska, A.
    Glogowski, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345